Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung Biologics Signs $262M Manufacturing Deal With European Pharma Company | Contract Pharma
Breaking News, Collaborations & Alliances

Samsung Biologics Signs $262M Manufacturing Deal With European Pharma Company

The agreement extends manufacturing commitments through 2033 and pushes Samsung Biologics’ cumulative contract value above $21.9 billion.

Editor’s Take: This deal comes as Samsung Biologics continues to secure long-term client commitments and fill available manufacturing capacity quickly.

Samsung Biologics has signed a $262 million manufacturing agreement with a European pharmaceutical company, according to a securities filing disclosed under Korean market rules.

The contract, which includes manufacturing commitments running through 2033, will be carried out at Samsung Biologics’ Songdo manufacturing site in South Korea. The company said the customer’s name and product-specific details will remain confidential under the terms of the agreement.

The new award underscores sustained demand for the company’s manufacturing capacity, with existing capacity across Samsung Biologics’ network continuing to be booked rapidly amid long-term demand from global biopharma clients.

Following the latest agreement, Samsung Biologics’ cumulative contract value has surpassed USD 21.9 billion, reinforcing the company’s business momentum as it expands capacity, broadens its portfolio, and builds out its global footprint.

More Samsung Biologics News

In July, Samsung Biologics launched an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG, a global CDMO specializing in peptide-based APIs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters